Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

NCT ID: NCT02454478

Last Updated: 2019-03-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-07-01
• Study Completion Date: 2017-05-29

Brief Summary

Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.

Conditions

Carcinoma, Renal Cell

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Lenvatinib plus Everolimus

Group Type: EXPERIMENTAL

Lenvatinib

Intervention Type: DRUG

Everolimus

Intervention Type: DRUG

Interventions

Lenvatinib

Intervention Type: DRUG

Everolimus

Intervention Type: DRUG

Other Intervention Names

Lenvatinib plus Everolimus orally once a day

Eligibility Criteria

Inclusion Criteria

1. Voluntary agreement to provide written informed consent of this study.

2. Willing and able to comply with all aspects of the protocol after being fully informed of the content.

3. Males or females aged greater than or equal to 20 years at the time of informed consent.

4. Histological or cytological confirmation of RCC.

5. Participants must have confirmed diagnosis of unresectable advanced and/or metastatic RCC.

6. Disease progression following vascular endothelial growth factor (VEGF) targeted therapy.

7. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0 to 1.

8. Adequately controlled blood pressure with or without the use of antihypertensive agents.

9. Participants with adequate function of major organs.

10. Adequate blood coagulation function, defined as international normalized ratio (INR) less than or equal to 1.5.

11. Survival expectation of 3 months or longer after study enrollment.

12. Participants with adequate washout period from the end of prior treatment to the start of study drug administration.

13. Females of childbearing potential must not have had unprotected sexual intercourse within 28 days before participant registration and must agree to use a highly effective method of contraception throughout the entire study period and for 30 days after final administration of investigational drug. If currently abstinent, the participant must agree to use a double-barrier method as described above if she becomes sexually active during this study period or for 30 days after investigational drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks before administration and must continue to use the same contraceptive during this study and for 30 days after investigational drug discontinuation.

14. Male participants and their female partners must meet the criteria above.

Exclusion Criteria

1. Participants with central nervous system (CNS) metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (example, radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment.

2. Prior exposure to lenvatinib.

3. Participants who have not recovered from toxicities to less than or equal to Grade 1 as a result of prior anticancer therapy, except alopecia.

4. Major surgery within 3 weeks prior to the first dose of lenvatinib.

5. Participants with a urine protein greater than or equal to 1 gram per 24 hours (g/24 hours).

6. Uncontrollable diabetes as defined by fasting glucose greater than 1.5* upper limit of normal (ULN).

7. Fasting total cholesterol greater than 7.75 millimole per liter (mmol/L) (greater than 300 milligram per decilitre [mg/dL]).

8. Fasting triglycerides greater than 2.5 * ULN.

9. Any condition that might affect the absorption of lenvatinib and/or everolimus.

10. Significant cardiovascular impairment.

11. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR monitoring.

12. Active hemoptysis.

13. Active infections that require systemic treatment.

14. Human immunodeficiency virus (HIV) positive.

15. Hepatitis B virus (HBV).

16. A history of interstitial pneumonia with clinical manifestation or as confirmed by means of diagnostic imaging.

17. Medical need for the continued use of potent or moderate inhibitors of cytochrome P450 3A (CYP3A) or P-gp, or potent or moderate inducer of CYP3A.

18. Known intolerance to lenvatinib (or any of the excipients) or known hypersensitivity to everolimus (or any of the excipients) or rapmycins (sirolimus, temsirolimus and so on).

19. Alcohol or drug dependency or abuse, inability to comply with every aspects of the study protocol, or any physical or mental conditions that in the opinion of the investigators would preclude the participant's participation in the study.

20. Females who are pregnant or breastfeeding (not eligible even she discontinues breastfeeding).

21. Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial.

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eisai Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Eisai Trial Site #1

Chiba, , Japan

Eisai Trial Site #1

Tokyo, , Japan

Eisai Trial Site #2

Tokyo, , Japan

Countries

Japan

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

E7080-J081-112

Identifier Type: -

Identifier Source: org_study_id